Phaseline

Companies › Bausch Health Americas

Bausch Health Americas: clinical trials, targets and expected readouts

6 active drug programs in 30 registered trials: 16 Phase 4, 9 Phase 2, 3 Phase 3, 2 Phase 1; Immunology, Infectious disease, Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IDP-122 Lotion
Topical corticosteroid (halobetasol propionate)
–Phase 4PsoriasisNov 2026
Rifaximin
Bacterial DNA-directed RNA polymerase inhibitor
–Phase 4Diarrhea; Hepatic Encephalopathy; Diarrhoea;Acute; Pouchitis …Apr 2027
Clindamycin
Bacterial 70S ribosome inhibitor
ERCC1, ERCC2Phase 4Acne Vulgaris; Skin Infection; Infection Control / Methods; Surgical Site Infection …Dec 2027
Brodalumab
Interleukin-17 receptor A antagonist
IL17RAPhase 4Psoriasis; Breast CancerDec 2028
Larsucosterol
Liver X receptor (LXR) activator
LXRPhase 3HepatitisNov 2027
plecanatide
Heat-stable enterotoxin receptor agonist
GUCY2CPhase 2Functional Constipation (FC)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03883269ClindamycinPhase 4Acne VulgarisImmunologyJun 2019
NCT04043897RifaximinPhase 2Microscopic ColitisImmunologyDec 2021
NCT05587036RifaximinPhase 2Healthy VolunteersImmunologyJul 2025
NCT05071716RifaximinPhase 3Hepatic EncephalopathyGastroenterologySep 2025
NCT05677282RifaximinPhase 4Diarrhoea;AcuteInfectious diseaseSep 2025
NCT05297448RifaximinPhase 3Hepatic EncephalopathyGastroenterologyFeb 2026
NCT05899140ClindamycinPhase 4Skin InfectionInfectious diseaseMar 2026
NCT07474194ClindamycinPhase 4Infection Control / MethodsInfectious diseaseApr 2026
NCT07267013ClindamycinPhase 2Aortic SurgeryCardiovascularJul 2026
NCT04580472ClindamycinPhase 4Surgical Site InfectionInfectious diseaseSep 2026
NCT03987763IDP-122 LotionPhase 4PsoriasisImmunologyNov 2026
NCT05398679ClindamycinPhase 4Endocarditis InfectiveCardiovascularDec 2026
NCT07894016ClindamycinPhase 4Wisdom Tooth RemovalOtherDec 2026
NCT04073290RifaximinPhase 4Hepatic EncephalopathyGastroenterologyDec 2026
NCT06727422RifaximinPhase 2IBS (Irritable Bowel Syndrome)GastroenterologyJan 2027
NCT06727422RifaximinPhase 2IBS (Irritable Bowel Syndrome)GastroenterologyJan 2027
NCT07285785RifaximinPhase 4DiarrheaInfectious diseaseApr 2027
NCT06673329BrodalumabPhase 1Breast CancerOncologyMay 2027
NCT05846399ClindamycinPhase 4Cat BiteInfectious diseaseJul 2027
NCT06312683RifaximinPhase 4PouchitisGastroenterologyJul 2027
NCT06058572RifaximinPhase 2Acute LeukemiaOncologyAug 2027
NCT06538077RifaximinPhase 4Hepatic EncephalopathyGastroenterologyAug 2027
NCT07723924plecanatidePhase 2Functional Constipation (FC)GastroenterologyOct 2027
NCT06718686RifaximinPhase 1Dementia Alzheimer TypeNeurologyOct 2027
NCT07428538LarsucosterolPhase 3HepatitisInfectious diseaseNov 2027
NCT07524946ClindamycinPhase 4Acne VulgarisImmunologyDec 2027
NCT07209371RifaximinPhase 2IgA Monoclonal Gammopathy of Undetermined SignificanceOncologyMay 2028
NCT05502913RifaximinPhase 2Metastatic Lung CancerOncologyJun 2028
NCT05137119ClindamycinPhase 4Staphylococcus Aureus BacteremiaInfectious diseaseDec 2028
NCT03240809BrodalumabPhase 4PsoriasisImmunologyDec 2028

Targets

ERCC1 (1) ERCC2 (1) IL17RA (1) LXR (1) GUCY2C (1)

Companies with the same targets

Samsung Bioepis Beijing Biotech

Companies built like this

IR INNOVATE RESEARCH PRIVATE Swedish Orphan Biovitrum Laboratorios Silanes S.A. de C.V. Jiangsu vcare pharmaceutical technology Octapharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.